{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:44:49Z","timestamp":1783691089580,"version":"3.55.0"},"reference-count":26,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2019-0025_s_001_w2aab3b7b5b1b6b1aab1c16b1Aa\">\n                    <jats:title id=\"d2883964e13467_w2aab3b7b5b1b6b1aab1c16b1aAa\">Background<\/jats:title>\n                    <jats:p>Ifosfamide has recently used as the intravenous component of bidirectional intraoperative chemotherapy (BDIC) with hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin plus doxorubicin. Little is known about the systemic toxicities of this BDIC regimen. Therefore, this study aimed to assess the toxicities of this treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0025_s_002_w2aab3b7b5b1b6b1aab1c16b2Aa\">\n                    <jats:title id=\"d2883964e13476_w2aab3b7b5b1b6b1aab1c16b2aAa\">Methods<\/jats:title>\n                    <jats:p>\n                      A prospective, cohort study, of patients who underwent the BDIC using intravenous ifosfamide 1,300\u2006mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and a HIPEC regimen of cisplatin 50\u2006mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      plus doxorubicin 15\u2006mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. Incidences and severity of leukopenia, neutropenia, thrombocytopenia, and erythrocytopenia were assessed over 45\u2006days after BDIC. Nephrotoxicity was assessed according to the RIFLE (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) classification system. Haemorrhagic cystitis was assessed by cystoscopy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0025_s_003_w2aab3b7b5b1b6b1aab1c16b3Aa\">\n                    <jats:title id=\"d2883964e13494_w2aab3b7b5b1b6b1aab1c16b3aAa\">Results<\/jats:title>\n                    <jats:p>A total of 18 patients were enrolled in the study. Grade 1 leukopenia developed in 11.1% of the patients, with 5.5% developed neutropenia. Thrombocytopenia developed in 61.1% of patients; it was grade 1 or 2 in most patients, but grade 3 in 1 (5.5%) patient. All patients developed erythrocytopenia after BDIC. Leukopenia, neutropenia, and thrombocytopenia resolved without treatment in all patients. Nephrotoxicity developed in 33.3% of the patients. One patient progressed to the End-stage kidney disease classification. No patient developed haemorrhagic cystitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0025_s_004_w2aab3b7b5b1b6b1aab1c16b4Aa\">\n                    <jats:title id=\"d2883964e13503_w2aab3b7b5b1b6b1aab1c16b4aAa\">Conclusions<\/jats:title>\n                    <jats:p>Intravenous ifosfamide combined with HIPEC using cisplatin plus doxorubicin yielded low rates of mild leukopenia. Mild thrombocytopenia was frequent, but severe suppression of platelets was uncommon. Nephrotoxicity developed in one-third of the patients, and haemorrhagic cystitis was absent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2019-0025","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T12:06:37Z","timestamp":1573128397000},"source":"Crossref","is-referenced-by-count":6,"title":["Systemic complications of the bidirectional intraoperative chemotherapy with intravenous ifosfamide and hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin plus doxorubicin"],"prefix":"10.1515","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-0966","authenticated-orcid":false,"given":"Hakeam","family":"Hakeam","sequence":"first","affiliation":[{"name":"Pharmaceutical Care Division , King Faisal Specialist Hospital and Research Centre , Riyadh , Saudi Arabia"},{"name":"School of Medicine , Alfaisal University , Riyadh , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzam","family":"Ayman","sequence":"additional","affiliation":[{"name":"King Faisal Oncology Centre , King Faisal Specialist Hospital and Research Centre , Riyadh , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al Taweel","family":"Waleed","sequence":"additional","affiliation":[{"name":"Department of Urology , King Faisal Specialist Hospital and Research Centre , Riyadh , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Amen","sequence":"additional","affiliation":[{"name":"King Faisal Oncology Centre , King Faisal Specialist Hospital and Research Centre , Riyadh , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"2025120909222924237_j_pp-2019-0025_ref_001_w2aab3b7b5b1b6b1ab1b5b1Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27:681\u20135.10.1200\/JCO.2008.19.716019103728","DOI":"10.1200\/JCO.2008.19.7160"},{"key":"2025120909222924237_j_pp-2019-0025_ref_002_w2aab3b7b5b1b6b1ab1b5b2Aa","doi-asserted-by":"crossref","unstructured":"Van der Speeten K, Stuart OA, Mahteme H, et al. Pharmacokinetic study of perioperative intravenous Ifosfamide. Int J Surg Oncol 2011;2011:185092.22312496","DOI":"10.1155\/2011\/185092"},{"key":"2025120909222924237_j_pp-2019-0025_ref_003_w2aab3b7b5b1b6b1ab1b5b3Aa","doi-asserted-by":"crossref","unstructured":"de Bree E, Michelakis D, Stamatiou D, et al. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum 2017;2:47\u201362.30911633","DOI":"10.1515\/pp-2017-0010"},{"key":"2025120909222924237_j_pp-2019-0025_ref_004_w2aab3b7b5b1b6b1ab1b5b4Aa","doi-asserted-by":"crossref","unstructured":"Van der Speeten K, Stuart OA, Mahteme H, et al. Pharmacology of perioperative 5-fluorouracil. J Surg Oncol 2010;102:730\u20135.2110492310.1002\/jso.21702","DOI":"10.1002\/jso.21702"},{"key":"2025120909222924237_j_pp-2019-0025_ref_005_w2aab3b7b5b1b6b1ab1b5b5Aa","doi-asserted-by":"crossref","unstructured":"Tascilar M, Loos WJ, Seynaeve C, et al. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist 2007;12:1351\u201360.10.1634\/theoncologist.12-11-135118055856","DOI":"10.1634\/theoncologist.12-11-1351"},{"key":"2025120909222924237_j_pp-2019-0025_ref_006_w2aab3b7b5b1b6b1ab1b5b6Aa","doi-asserted-by":"crossref","unstructured":"Song T, Kim MK, Lee YY, et al. Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer. Cancer Chemother Pharmacol 2013;72:653\u201360.2391269310.1007\/s00280-013-2241-7","DOI":"10.1007\/s00280-013-2241-7"},{"key":"2025120909222924237_j_pp-2019-0025_ref_007_w2aab3b7b5b1b6b1ab1b5b7Aa","doi-asserted-by":"crossref","unstructured":"Kuroda M, Urano M, Reynolds R. Thermal enhancement of the effect of ifosfamide against a spontaneous murine fibrosarcoma, FSa-II. Int J Hyperthermia 1997;13:125\u201331.10.3109\/026567397090564369024933","DOI":"10.3109\/02656739709056436"},{"key":"2025120909222924237_j_pp-2019-0025_ref_008_w2aab3b7b5b1b6b1ab1b5b8Aa","doi-asserted-by":"crossref","unstructured":"Dechant KL, Brogden RN, Pilkington T, Faulds D. Ifosfamide\/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 1991;42:428\u201367.1720382","DOI":"10.2165\/00003495-199142030-00006"},{"key":"2025120909222924237_j_pp-2019-0025_ref_009_w2aab3b7b5b1b6b1ab1b5b9Aa","doi-asserted-by":"crossref","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359\u201374.10.1007\/978-1-4613-1247-5_238849962","DOI":"10.1007\/978-1-4613-1247-5_23"},{"key":"2025120909222924237_j_pp-2019-0025_ref_010_w2aab3b7b5b1b6b1ab1b5c10Aa","doi-asserted-by":"crossref","unstructured":"Stillwell TJ, Benson RC, Jr. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer 1988;61:451\u20137.10.1002\/1097-0142(19880201)61:3<451::AID-CNCR2820610308>3.0.CO;2-G3338015","DOI":"10.1002\/1097-0142(19880201)61:3<451::AID-CNCR2820610308>3.0.CO;2-G"},{"key":"2025120909222924237_j_pp-2019-0025_ref_011_w2aab3b7b5b1b6b1ab1b5c11Aa","unstructured":"Bethesda M. Applications: INCNGoCT, National Cancer Institute, November 2017."},{"key":"2025120909222924237_j_pp-2019-0025_ref_012_w2aab3b7b5b1b6b1ab1b5c12Aa","doi-asserted-by":"crossref","unstructured":"Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204\u2013212.15312219","DOI":"10.1186\/cc2872"},{"key":"2025120909222924237_j_pp-2019-0025_ref_013_w2aab3b7b5b1b6b1ab1b5c13Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221:29\u201342.10.1097\/00000658-199501000-000047826158","DOI":"10.1097\/00000658-199501000-00004"},{"key":"2025120909222924237_j_pp-2019-0025_ref_014_w2aab3b7b5b1b6b1ab1b5c14Aa","doi-asserted-by":"crossref","unstructured":"Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 2013;39:1435\u201343.2420943010.1016\/j.ejso.2013.09.030","DOI":"10.1016\/j.ejso.2013.09.030"},{"key":"2025120909222924237_j_pp-2019-0025_ref_015_w2aab3b7b5b1b6b1ab1b5c15Aa","doi-asserted-by":"crossref","unstructured":"Hakeam HA, Breakiet M, Azzam A, et al. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail 2014;36:1486\u201391.10.3109\/0886022X.2014.94975825155314","DOI":"10.3109\/0886022X.2014.949758"},{"key":"2025120909222924237_j_pp-2019-0025_ref_016_w2aab3b7b5b1b6b1ab1b5c16Aa","doi-asserted-by":"crossref","unstructured":"Tabuchi Y, Shinka S, Ishida H. The effects of anesthesia and surgery on count and function of neutrophils. J Anesth 1989;3:123\u201331.10.1007\/s005409003012315236027","DOI":"10.1007\/s0054090030123"},{"key":"2025120909222924237_j_pp-2019-0025_ref_017_w2aab3b7b5b1b6b1ab1b5c17Aa","doi-asserted-by":"crossref","unstructured":"Perez-Ruixo C, Valenzuela B, Peris JE, et al. Neutrophil dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin. Clin Pharmacokinet 2013;52:1111\u201325.2382861710.1007\/s40262-013-0092-3","DOI":"10.1007\/s40262-013-0092-3"},{"key":"2025120909222924237_j_pp-2019-0025_ref_018_w2aab3b7b5b1b6b1ab1b5c18Aa","doi-asserted-by":"crossref","unstructured":"Noe DA, Graham SM, Luff R, et al. Platelet counts during rapid massive transfusion. Transfusion 1982;22:392\u20135.10.1046\/j.1537-2995.1982.22583017465.x7123635","DOI":"10.1046\/j.1537-2995.1982.22583017465.x"},{"key":"2025120909222924237_j_pp-2019-0025_ref_019_w2aab3b7b5b1b6b1ab1b5c19Aa","doi-asserted-by":"crossref","unstructured":"Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer 2002;94:492\u20139.10.1002\/cncr.1017611900234","DOI":"10.1002\/cncr.10176"},{"key":"2025120909222924237_j_pp-2019-0025_ref_020_w2aab3b7b5b1b6b1ab1b5c20Aa","doi-asserted-by":"crossref","unstructured":"Kusamura S, Baratti D, Younan R, et al. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol 2007;14:2550\u20138.10.1245\/s10434-007-9429-117558537","DOI":"10.1245\/s10434-007-9429-1"},{"key":"2025120909222924237_j_pp-2019-0025_ref_021_w2aab3b7b5b1b6b1ab1b5c21Aa","unstructured":"Van Dyk JJ, Falkson HC, Van der Merwe AM, Falkson G. Unexpected toxicity in patients treated with iphosphamide. Cancer Res 1972;32:921\u20134.4552918"},{"key":"2025120909222924237_j_pp-2019-0025_ref_022_w2aab3b7b5b1b6b1ab1b5c22Aa","unstructured":"Creaven PJ, Allen LM, Cohen MH, et al. Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724). Cancer Treat Rep 1976;60:445\u20139.1277220"},{"key":"2025120909222924237_j_pp-2019-0025_ref_023_w2aab3b7b5b1b6b1ab1b5c23Aa","doi-asserted-by":"crossref","unstructured":"Rossi R, Godde A, Kleinebrand A, et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 1994;12:159\u201365.10.1200\/JCO.1994.12.1.1598270973","DOI":"10.1200\/JCO.1994.12.1.159"},{"key":"2025120909222924237_j_pp-2019-0025_ref_024_w2aab3b7b5b1b6b1ab1b5c24Aa","doi-asserted-by":"crossref","unstructured":"Liu JQ, Cai GY, Wang SY, et al. The characteristics and risk factors for cisplatin-induced acute kidney injury in the elderly. Ther Clin Risk Manag 2018;14:1279\u201385.10.2147\/TCRM.S16553130100726","DOI":"10.2147\/TCRM.S165531"},{"key":"2025120909222924237_j_pp-2019-0025_ref_025_w2aab3b7b5b1b6b1ab1b5c25Aa","doi-asserted-by":"crossref","unstructured":"Gagniere J, Veziant J, Pereira B, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the elderly: is it reasonable? A meta-analysis. Ann Surg Oncol 2018;25:709\u201319.10.1245\/s10434-017-6313-529282602","DOI":"10.1245\/s10434-017-6313-5"},{"key":"2025120909222924237_j_pp-2019-0025_ref_026_w2aab3b7b5b1b6b1ab1b5c26Aa","doi-asserted-by":"crossref","unstructured":"Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 1995;21:33\u201364.10.1016\/0305-7372(95)90010-17859226","DOI":"10.1016\/0305-7372(95)90010-1"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/4\/4\/article-20190025.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0025\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0025\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:58:09Z","timestamp":1765277889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0025\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,11,2]]},"published-print":{"date-parts":[[2019,11,26]]}},"alternative-id":["10.1515\/pp-2019-0025"],"URL":"https:\/\/doi.org\/10.1515\/pp-2019-0025","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"article-number":"20190025"}}